Corrigendum to "Natural prevalence of NS5A polymorphisms in subjects infected with Hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors" [J. Clin. Virol. 57 (2013) 13-18], doi: 10.1016/j.jcv.2012.12.020;Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors

Journal of Clinical Virology

Volumn 57, Issue 1, 2013, Pages 13-18

  Hernandez, Dennis ^a   Zhou, Nannan ^a   Ueland, Joseph ^a   Monikowski, Aaron ^a   McPhee, Fiona ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Daclatasvir (DCV); GS 5885; Hepatitis C virus; NS5A

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; GS 5885; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A REPLICATION COMPLEX INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; AUSTRALIA; DRUG POTENCY; EUROPE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL;

EID: 84875804486     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.02.008     Document Type: Erratum

References (36)

1. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004, 44(1):20-29.
2. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85(Pt 11):3173-3188.
3. Zarife M.A., Silva L.K., Silva M.B., Lopes G.B., Barreto M.L., Teixeira Mda G., et al. Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study. Trans R Soc Trop Med Hyg 2006, 100(7):663-668.
4. Das B.R., Kundu B., Khandapkar R., Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002, 45(3):323-328.
5. Idrees M., Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008, 8:69.
6. Stamouli M., Panagiotou I., Kairis D., Michopoulou A., Skliris A., Totos G. Genotype distribution in chronic hepatitis C patients in Greece. Clin Lab 2012, 58(1-2):173-176.
7. Chlabicz S., Flisiak R., Kowalczuk O., Grzeszczuk A., Pytel-Krolczuk B., Prokopowicz, et al. Changing HCV genotypes distribution in Poland-relation to source and time of infection. J Clin Virol 2008, 42(2):156-159.
8. de Vries M.J., te Rijdt B., van Nieuwkerk C.M. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med 2006, 64(4):109-113.
9. Wang Y., Tao Q.M., Zhao H.Y., Tsuda F., Nagayama R., Yamamoto K., et al. Hepatitis C virus RNA and antibodies among blood donors in Beijing. J Hepatol 1994, 21(4):634-640.
10. Gottwein J.M., Scheel T.K., Jensen T.B., Ghanem L., Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011, 141(3):1067-1079.
11. Gao M., Nettles R.E., Belema M., Snyder L.B., Nguyen V.N., Fridell R.A., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465(7294):96-100.
12. Shih I.H., Vliegen I., Peng B., Yang H., Hebner C., Paeshuyse J., et al. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2011, 55(9):4196-4203.
13. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Müh U., Welker M., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132(5):1767-1777.
14. Vermehren J., Susser S., Lange C.M., Forestier N., Karey U., Hughes E., et al. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepat 2012, 19(2):120-127.
15. Nettles R.E., Gao M., Bifano M., Chung E., Persson A., Marbury T.C., et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, 54(6):1956-1965.
16. Hézode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360(18):1839-1850.
17. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360(18):1827-1838.
18. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
19. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1207-1217.
20. Foster G.R., Hézode C., Bronowicki J.P., Carosi G., Weiland O., Verlinden L., et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011, 141(3). 881-9.e1.
21. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):1433-1444.
22. Silva M., Kasserra C., Gupta S., Treitel M., Hughes E., O'Mara E., et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Hepatol Int 2011, 5:3-558.
23. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140(5):346-355.
24. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 2012, 56(6). iiA-vA, 2A-1234A.
25. Fridell R.A., Wang C., Sun J.H., O'Boyle D.R., Nower P., Valera L., et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011, 54(6):1924-1935.
26. Fridell R.A., Qiu D., Wang C., Valera L., Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010, 54(9):3641-3650.
27. McPhee F., Hernandez D., Yu F., Ueland J., Chayama K., Toyota J., et al. A description of virologic escape in HCV genotype 1-infected patients treated with daclatasvir (BMS-790052) in combination with ribavirin and peginterferon alfa-2a or peginterferon alfa-2b. J Hepatol 2012, 56(S2):S473.
28. Sun J.H., O'Boyle D.R., Zhang Y., Wang C., Nower P., Valera L., et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012, 55(6):1692-1699.
29. Wang C., Jia L., Huang H., Qiu D., Valera L., Huang X., et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 2012, 56(3):1588-1590.
30. Lawitz E.J., Gruener D., Hill J.M., Marbury T., Moorehead L., Mathias A., et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012, 57(1):24-31.
31. Gottwein J.M., Scheel T.K., Callendret B., Li Y.P., Eccleston H.B., Engle R.E., et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 2010, 84(10):5277-5293.
32. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28(10):2731-2739.
33. Kato T., Furusaka A., Miyamoto M., Date T., Yasui K., Hiramoto J., et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001, 64(3):334-339.
34. Suzuki F., Sezaki H., Akuta N., Suzuki Y., Seko Y., Kawamura Y., et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012, 54(4):352-354.
35. Hernandez D., Ueland J., Yu F., Kirk M., Zhou N., Monikowski A., et al. Characterization of HCV genotype 1 NS5A resistance variants from the phase 2b COMMAND-1 study: daclatasvir plus peginterferon-alfa/ribavirin in treatment-naive patients. Hepatology 2012, 56(4):580A.
36. McPhee F., Hernandez D., Zhou N., Ueland J., Monikowski A., Tanveen T., et al. Characterization of HCV NS5A resistance variants in naive patients infected with genotypes 2 and 3 receiving short-term treatment of daclatasvir in combination with pegylated interferon-alfa and ribavirin. Hepatology 2012, 56(4):579A.